Review of CMS’ coverage with evidence development program exposes a need to improve program transparency and clarify requirements and timetables for reporting to improve access to novel therapies.
Sana M. Al-Khatib, MD, MHS
Advertisement
Articles by Sana M. Al-Khatib, MD, MHS
Advertisement
Latest Updated Articles
- Coverage With Evidence Development: Where Are We Now?
April 7th 2022
Advertisement
Advertisement
Trending on AJMC
1
Trump Childhood Vaccine Order: What It Means for Parents and Payers
2
FDA Proposes GRAS Rule, Advances Ultra-Processed Food Definition
3
Cardiac Amyloidosis Diagnosis Lags After Heart Failure Onset
4
Orelabrutinib Cuts Progression Risk 68% in Frontline CLL/SLL
5